Lysulin Studies

Recent Publications by John F. Burd, PhD.

  • Burd J. Lysulin™, a new supplement for Nutritional Support for People with Diabetes and Pre-diabetes (those at risk of developing diabetes). Diabetes Management, 8(2), 38– 40 (2018). Click here to read the article.
  • Burd JF and Noetzel V: 2018 – Lysulin – Effective OTC Nutritional Supplement for Type 2 Diabetes. 2018. Click here to read the article.
  • Burd JF, Melero FAA and Noetzel V: Hemoglobin a1c (Hba1c) shows improvement in glycemic control in as little as two weeks following the addition of lysulin™, to the treatment of diabetes. Diabetes Management, 8(3), 82–84 (2018). Click here to read the article.
  • Burd JF, Melero FAA and Noetzel V: Largest Reported 3 Month Drop in HbA1c for a Newly Diagnosed Patient with Type 2 Diabetes. Int J Diabetes Complications, 2(3), 9-10 (2018). Click here to read the article.
  • Burd JF, Noetzel V, Gonzalez A and Melero FAA: A Double-Blind Placebo-Controlled Pilot Study of Daily Oral Supplementation of LysulinTM in People with Type 2 Diabetes. Diabetes Management 2018 Diabetes Management, 8(6), 154–162 (2018).
  • Burd J F and Noetzel V: People With Type 2 Diabetes See Considerable HbA1c Improvement in 1 month Using Lysulin. J Obesity and Diabetes, 2, 11-12 (2018).
  • Burd JF, Noetzel V and Walsh MJ: Lysulin: Improvement in Glycemic Control Compared to Type 2 Drugs. Int J Diabetes and Endocrinology, 1, 1-9 (2019).
  • Burd JF and Noetzel V: Lysulin: Successfully Targeting a New Mechanism for Diabetes Treatment. Diabetes and its Complications, 3, 1-2 (2019).
  • Burd, JF: Glucose Toxicity- The Worldwide Problem and the Natural Solution. J Diabetes Care, 1, 13-16 (2019).
  • Burd, JF: measures of Glycemic Control and The Case for More Frequent Testing of HbA1c. Nursing and Primary Care, 3, 1-3 (2019)

20 years of scientific studies that prove the benefits of Lysulin’s ingredients

 

Power of Medical Nutrition Therapy in Diabetes

  • Diabetes Care (2019) 42, 031–754. Nutrition Therapy for Adults With Diabetes or Prediabetes.  “Research suggests that medical nutrition therapy for adults with type 2 diabetes can achieve hemoglobin A1c reductions similar to or greater than what could be expected with medications, according to the report.
  • Diabetes Care (2019) 42, 727-730. Nutritional Strategies for Prevention and Management of Diabetes: Consensus and Uncertainties.

 

Lysine Lowers Glucose and Glycated Proteins

  • Am J Clin Nutr.2009 90 (2):314-20. “Lysine ingestion markedly attenuates the glucose response to ingested glucose without a change in insulin response”.  Available from: https://doi.org/10.3945/ajcn.2008.27381
  • Acta medica Iranica2016 54: 24-31. “The findings…provide convincing evidence on the usefulness of lysine supplementation as a new adjunct therapy for diabetes.”  Available from: http://acta.tums.ac.ir/index.php/acta/article/view/5385
  • Diabetes/metabolism research and reviews2008 24 (1) 64-73.”RESULTS: We found that L-Lysine therapy prevented diabetic- induced increases in Glucose, AGE, HbA(1c), triglyceride, total- and LDL- cholesterol.”  Available from: https://doi.org/10.1002/dmrr.769
  • Diabetologia(1993) 36: 797-801- Diabetic rat study. this study has demonstrated that lysine treatment in chemically-induced diabetes is capable of reducing glycated proteins and it could potentially delay the appearance of the late pathologies associated with diabetic hyperglycemia and aging.  Available from: https://link.springer.com/content/pdf/10.1007/BF00400352.pdf
  • Eye Res1993 56, 623-628. Lysine and glucose undergo non-enzymatic glycation ay physiological pH and temperature with glucose and compete for this reaction with lens proteins. Lysine lowered the extent of glycation of lens proteins significantly in glucose-treated homogenates of normal lens from humans. Scavenging of intracellular glucose and thereby protecting the lens proteins from excessive glycation appears to be the mechanism of action by which lysine could exercise a beneficial effect on cataract formation.  Available from: https://doi.org/10.1006/exer.1993.1167
  • Eye Res.(1998) 67, 597-601. While the blood sugar levels remain high in the diabetic controls, there was a phenomenal reduction of blood sugar levels in lysine or amino acids-fed groups. Lysine, in particular, has the prospect of therapeutic value in the control of diabetes. Normal levels of glycosylated hemoglobin in groups III and IV confirm diabetic control by lysine. The mechanism may be mostly through scavenging of glucose by amino acids. All the diabetic rats developed cataract (Fig. 1) at the end of 70-90 days. Interestingly, four out of six in group IV receiving lysine alone or amino acids orally did not develop cataract. Dietary intake a mixture of essential amino acids, chiefly lysine, may ward off or delay cataract formation. Available from: https://doi.org/10.1006/exer.1998.0547
  • Med Sci Monit, 2002 8(3) 131-137. In a study with 77 Type 2 patients divided into 4 groups. HbA1c dropped from 9 to 8.2% in the group taking lysine. Available from: https://www.medscimonit.com/download/index/idArt/420914
  • Alternative Medicine Review2007, 12, # 2, 169-172. Reports amazing utility of lysine for treatment of herpes. “In general, lysine supplementation is very safe. Doses up to 3 g daily are typically well-tolerated.”  Available from: http://archive.foundationalmedicinereview.com/publications/12/2/169.pdf
  • Complementary and Alternative Medicine(2015) 15:193, It was concluded that lysine attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine as IL-6 and enhance antioxidant capacity.Available from: https://doi.org/10.1186/s12906-015-0729-x

 

Zinc Lowers Glucose and Glycated Proteins and Improves the Lipid Profile.

  • Ren Fail2011; 33: 466-467. “Zinc deficiency has been documented in patients with CKD. In a recent editorial, the authors reported zinc deficiency in 40%-78% of hemodialysis (HD) patients.” Available from: https://doi.org/10.3109/0886022X.2011.568144
  • Diabetology & Metabolic Syndrome(2012), 4:13. “In conclusion, this first comprehensive systematic review and meta-analysis on the effects of Zinc supplementation in patients with diabetes demonstrates that Zinc supplementation has beneficial effects on glycemic control and promotes healthy lipid parameters.” Available from: https://doi.org/10.1186/1758-5996-4-13
  • Nutrition & Metabolism(2015) 12:26. Zinc supplementation significantly reduced total cholesterol, LDL cholesterol, and triglycerides. In addition to that, Zinc supplementation in non-healthy patients demonstrated a significant elevation of HDL cholesterol. Therefore it may have the potential to reduce the incidence of atherosclerosis-related morbidity and mortality especially in non-healthy patients who are at risk of atherosclerosis.   Available from: https://doi.org/10.1186/s12986-015-0023-4
  • DARU Journal of Pharmaceutical Sciences(2015) 23:44. “Numerous in-vitro and in-vivo studies have shown that Zinc has beneficial effects in both type-1 and type-2 diabetes. It is evident from the findings of the present systematic review, that Zinc plays an important role in β-cell function, insulin action, glucose homeostasis and the pathogenesis of diabetes and its complications.”   Available from: https://doi.org/10.1186/s40199-015-0127-4
  • Health, 2016, 8, 344-352. “In summary, lower zinc levels are related to end-stage renal disease patients in hemodialysis and supplementation seems to be a promising approach in such cases.” Available from: http://dx.doi.org/10.4236/health.2016.84036
  • Nihon Rinsho2016 74(7):1138-43. “In this article, we describe zinc deficiency in patients with CKD. The ability that zinc supplementation improves their anemia in CKD patients is also described.” Available from: https://www.ncbi.nlm.nih.gov/pubmed/27455803
  • J Diabetes2017 “Zinc supplementation reduced blood glucose and insulin resistance while improving β-cell function. Furthermore, disease progression to diabetes was reduced and beneficial effects of supplementation were also noted on total and LDL cholesterol.” Available from: https://doi.org/10.1111/1753-0407.12621
  • Journal of Diabetes(2017) doi: 10.1111/jdb.12621. Usage of Zinc in pre-diabetes: A clinical trial. 200 patients with prediabetes studied in a double-blind study. “The FPG, OGTT, total and LDL cholesterol were significantly reduced in the Zinc group, with significant improvement in β-cell function.” LDL dropped by 28% and beta cell function improved by 57%. In a 2 year follow up, fewer patients on zinc went on to develop Type 2 diabetes; 11% on zinc versus 25% in the control group. Available from: https://doi.org/10.1111/1753-0407.12621
  • J Trace Elem Med Biol. 2017 44:132-136. Association of reduced zinc status with poor glycemic control in individuals with type 2 diabetes mellitus.  “According to our study results, conclude that T2DM individuals with reduced zinc status exhibited poor glycemic control.”

 

Vitamin C Lowers Glucose and HbA1c

  • Advances in Pharmacological Sciences Volume(2011), Article ID 195271, doi:10.1155/2011/195271 “The absence of any substantial side effects, cheaper cost, improvement in FBS, PPBS, and HBA1c, and the fact that plasma ascorbic acid levels are decreased in DM and increased after oral supplementation make it a particularly attractive therapeutic adjuvant in the treatment of type 2 DM.”Available from: https://doi.org/10.1155/2011/195271
  • World Journal of Analytical Chemistry2015 (1A) 6 Effect of Vitamin C on Blood Glucose and Glycosylated Hemoglobin in Type II Diabetes Mellitus. In conclusion, oral supplementation of vitamin C reduces FBG, two hours PPBG, and improves HbA1c. Available from: http://pubs.sciepub.com/wjac/3/1A/2/index.html

 

Glycated Proteins are the Cause of Many Disease Complications.

  • Acad. Sci.1995 92 3744-3748, We conclude that AGEs may contribute to the increased severity of stroke associated with diabetes and other conditions characterized by AGE accumulation. Available from: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=7731977
  • CURRENT SCIENCE 2002 83: 12, 1515-1521. The findings of the UKPDS which indicate for every 1% increase in glycated hemoglobin levels, a 37% increase in microvascular disease was seen. Available from: http://hdl.handle.net/1808/17792
  • Diabetes Research and Clinical Practice67 (2005) 3–21. “Increased glycation and, in particular, accumulation of tissue and serum glycated proteins have an important role in the pathogenesis of diabetic complications. The role of glycated proteins in the pathogenesis of retinopathy, cataract, atherosclerosis, neuropathy, nephropathy, diabetic embryopathy (newborn complications with a diabetic mother) and impaired wound healing are considered.” Available from: https://doi.org/10.1016/j.diabres.2004.09.004
  • Kerala Journal of Ophthalmology2006 XVIII 3 167-173. “To sum up, protein glycation may play a pathogenic role in diabetic and age related dysfunction of the eye. The role of glycated protein in cataract formation has been extensively studied in both aged & diabetic lens where glycated proteins are significantly elevated. Glycated proteins are important in the development of age-related macular degeneration. Glycated proteins are significantly increased in diabetic retinopathy patients.” Available from: https://pdfs.semanticscholar.org/52c9/3fd21267219c4cb2ec76c1e99ff2b9a6ae6b.pdf
  • SLEEP2006; 29 (3):329-333. The formation and accumulation of advanced glycation endproducts (AGEs) has been implicated in the progression of age-related diseases such as diabetes mellitus and atherosclerosis. We hypothesize that AGE concentrations may be increased in subjects with obstructive sleep apnea (OSA). Serum levels of AGEs were increased in nondiabetic subjects with OSA and were associated with the severity of OSA. Available from: https://doi.org/10.1093/sleep/29.3.280
  • Neurobiology of Aging(2009) doi:10.1016/j.neurobiolaging.2009.04.016 “The ‘glycation theory of aging’, as the underlying common principle of degeneration, unites some of the neuropathological and biochemical findings in Alzheimer’s Disease. AGEs may contribute to several processes underlying dementia…” Available from: https://doi.org/10.1016/j.neurobiolaging.2009.04.016
  • N Engl J Med2010 9800-811. “In nondiabetic adults, glycated hemoglobin was more strongly associated with risks of cardiovascular disease and death from any cause as compared with fasting glucose.” Available from: https://doi.org/10.1056/NEJMoa0908359
  • Dermato-Endocrinology(2012) 4:3, 259–270. “There is ample evidence that glycated proteins play an important role in skin aging.” Available from: https://doi.org/10.4161/derm.22028
  • Korean J Physiol Pharmacol2014, 18 1-14. “Protein glycation and formation of advanced glycation end products (AGEs) play an important role in the pathogenesis of diabetic complications like retinopathy, nephropathy, neuropathy, cardiomyopathy along with some other diseases such as rheumatoid arthritis, osteoporosis, and aging. Glycation of proteins interferes with their normal functions by disrupting molecular conformation, altering enzymatic activity, and interfering with receptor functioning.” Available from: https://dx.doi.org/10.4196%2Fkjpp.2014.18.1.1
  • Scars, Burns and Healing 2016 DOI: 10.1177/2059513116676828. “Abundant evidence supports the pathological effects of glycated proteins in ageing and wound healing” Available from: http://dx.doi.org/10.1177/2059513116676828
  • Diabetes Care2017 40, 591-598. “In summary, these findings suggest that the effect of hyperglycemia and subsequent increased levels of AGEs in patients with long-standing Type 2 diabetes may have long-lasting adverse effects on the development of macrovascular complications.” Available from: https://doi.org/10.2337/dc16-1875
  • J Amer Col Cardiology(2017) 70: 16 2020-2021. “Glycation of HDL leads to dysfunctional HDL promoting senescence and atherosclerosis.” Available from: https://doi.org/10.1016/j.jacc.2017.08.051
  • Clinical Science(2017) 131 1069–1092. “Strong links between glycated proteins and Chronic Kidney Disease have been reported over the last 25 years.”Available from: https://doi.org/10.1042/CS20160823

 

HbA1c Publications

  • Diabetes Spectrum2015; 28 (3): 201-208. Selection an A1C Point-of-Care Instrument. All devices must meet quality measures set by the NGSP for clinical results to be considered reliable and accurate. Currently, the DCA Vantage, Afinion, and A1CNow devices have met NSGP criteria for analytical performance, which makes them acceptable options for POC A1C testing. Available from: https://doi.org/10.2337/diaspect.28.3.201
  • J Diabetes Sci Technol.2016 Oct; 10(6): 1303–1307. Average RBC life span is 80 ± 10.9 days. Of HbA1c change toward treatment goal value, 50% is reached in about 30 days. Available from: https://dx.doi.org/10.1177%2F1932296816659885

"I am happy to report that my HbA1c percentage was 5.8% today after one month of taking Lysulin 3 servings a day. As you may recall, the starting A1c percentage was 6.2%."

Gene T. - Sunnyvale, CA

"I am feeling great! Better than any time last 2 years! I am recommending your product to anyone I know that has diabetes."

Mike T. - Sebring, F

"Yes, my blood sugars are stable with no insulin for 40 plus day."

Gary W. - Carlsbad, C

"John, I got the new kit. I tested my A1C today. It was 6.5 on 4/14. Today it was 5.4. I do like the chewable tablets. I still just swallow them but it is so much easier."

Karen M. - Fort Wayne, IN

"Using Lysulin, my glucose numbers stabilized."

Lester O. - Bristol, IN

"One month ago my A1C was 6.3, today it was 6.2. The line on my CGM has been much steadier, many fewer peaks and valleys. Thanks so much."

Cary T. - La Jolla, CA

"When I started taking Lysulin on 4/30, my A1C was at 6.8 Thirty days later on 5/30 with both low carb eating and Lysulin (3 per day) A1C was down to 6.0 That’s quite a drop for only 30 days! And I’m very happy about it."

Carla M. - San Diego, CA

"I have had Type 2 diabetes for over 20 years and have been using 1000 mg of Metformin twice a day. In May, 2018, I was hospitalized for heart attack, and when I returned home, I had a hard time controlling my blood sugar. In June my HbA1c was 6.8% and I started taking Lysulin. After 2 months with Lysulin, my A1C has dropped to 5.8! And I have reduced my Metformin as well! I can now participate my cardiac rehab program. I am very satisfied with Lysulin and I am recommending it to my sister-in-law who also has T2D."

Bob W. - Fort Wayne, IN

"I was diagnosed less than 3 months ago with Type 2 diabetes. I started immediately using Lysulin and Metformin and my HbA1c has dropped from over 12 to 5.8. I am thrilled."

Marc R. - Daytona Beach, FL

"I can’t begin to tell you how much I love your product. After only a month, my HbA1C is down by .4, I have been able to reduce my nighttime insulin dosage, and I haven’t used mealtime insulin in the last 2.5 weeks. My daily numbers are better than they’ve ever been. So glad to have had a chance to try your product. Thank you!"

Teresa C. - CA

"On a recent visit to my doctor I was shocked to hear that my HbA1c was 7.4%, since I had never been diagnosed with diabetes. I learned of Lysulin and started taking 2 tablets a day. After one month of use, my HbA1c had dropped to 6.1%! I am eager to see what it will drop to after 2 and 3 months of use. What a great product."

Charles B. - IN

"I was diagnosed with Type 2 diabetes in 2014 with a HbA1c of 13.9. Since I started Lysulin I have stopped taking Trulicity and am now taking just 500 mg Metformin twice a day plus my daily Lysulin. In December 2017 my HbA1c was 7.0. Since taking Lysulin, my HbA1c dropped to 6.1 in January and I am thrilled to report that on February 24th it has dropped to 5.0. I plan to talk to my doctor about reducing my dose of Metformin. I am so pleased that I learned about Lysulin and I am thankful for the drop in my HbA1c. (More good news on 2-25-18) My husband was told on January 24th that he had prediabetes with an HbA1c of 5.7. He immediately started daily Lysulin and after 1 month his HbA1c has dropped to 4.9 %. This is amazing!"

Deeana M. - IN

"My husband started using Lysulin 3 months ago. The first test A1C level read 6.9, Second month 6.6, and this month 6.3. Not only has his A1C gone down, the last doctor's visit for his high blood pressure was the lowest in 5 years. He's been on high blood medication since the age of 28. We will continue to use Lysulin and work on better eating habits. At this rate he'll be below the 6's in no time! Thank you Lysulin."

Julie N. - FL

Watch Dr. John Burd’s presentation about the benefits of taking Lysulin for people with diabetes.